Drug-induced Fatty Liver Disease: Pathogenesis and Treatment
| Autor: | George Y. Wu, Vjera Ninčević, Sonja Vukadin, Kristina Duspara, Tea Omanović Kolarić, Lucija Kuna, Kristina Bojanic, Nikola Raguz-Lucic, Martina Smolić |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Liver injury
Polypharmacy medicine.medical_specialty Metabolic dysfunction-associated fatty liver disease Hepatology Drug-induced liver injury business.industry Fatty liver Disease Review Article medicine.disease Bioinformatics Free fatty acids Obesity Pharmacogenetics Epidemiology Medicine Metabolic syndrome business Reactive oxygen species Metabolic dysfunction-associated fatty liver disease Drug-induced liver injury Reactive oxygen species Free fatty acids Pharmacogenetics |
| Zdroj: | Journal of Clinical and Translational Hepatology |
| ISSN: | 2225-0719 |
| Popis: | Metabolic dysfunction-associated fatty liver disease (commonly known as MAFLD) impacts global health in epidemic proportions, and the resulting morbidity, mortality and economic burden is enormous. While much attention has been given to metabolic syndrome and obesity as offending factors, a growing incidence of polypharmacy, especially in the elderly, has greatly increased the risk of drug-induced liver injury (DILI) in general, and drug-induced fatty liver disease (DIFLD) in particular. This review focuses on the contribution of DIFLD to DILI in terms of epidemiology, pathophysiology, the most common drugs associated with DIFLD, and treatment strategies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|